Drug Trial Radar · NCT06005493
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
392
Planned (sponsor's estimate)
Start
Jul 11, 2023
Primary completion
Mar 16, 2029
Study completion Mar 16, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Conditions
- Gastric Cancer
- Gastro-esophageal Junction Cancer
- Pancreatic Ductal Adenocarcinoma
- Esophageal Adenocarcinoma
Interventions
AZD5863Drug
T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
AZD2936Drug
Rilvegostomig is a bi-specific antibody targeting the immunosuppressive PD-1 and TIGIT pathways.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of patients with adverse eventsTime frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
- The number of patients with adverse events of special interestTime frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
- The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: From first dose of study drug until the end of Cycle 1
- The number of patients with serious adverse eventsTime frame: From first dose of study drug up to 90 days post last dose and prior to start of subsequent anticancer therapy
- Objective Response Rate (ORR)Time frame: From first dose of study drug to progressive disease or death in the absence of disease progression (approx. 2 years)
Locations
25 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Jacksonville, Florida · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Shandong, China · Recruiting
Research Site
Toulouse, France · Recruiting
Research Site
Villejuif, France · Recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Kōtoku, Japan · Recruiting
Research Site
Amsterdam, Netherlands · Recruiting
Research Site
Groningen, Netherlands · Recruiting
Research Site
Rotterdam, Netherlands · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Kaohsiung City, Taiwan · Recruiting
Research Site
Tainan, Taiwan · Recruiting
Research Site
Taoyuan, Taiwan · Recruiting
Research Site
Dundee, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Metropolitan Borough of Wirral, United Kingdom · Recruiting
Research Site
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.